登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月20日，A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-22

  • A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19

    Drifa Belhadi, Nathan Peiffer-Smadja, Yazdan Yazdanpanah, France Mentré, Cédric Laouénan

    doi: https://doi.org/10.1101/2020.03.18.20038190

    Abstract

    Background: Although a number of antiviral agents have been evaluated for coronaviruses there are no approved drugs available. To provide an overview of the landscape of therapeutic research for COVID-19, we conducted a review of registered clinical trials. Methods: A review of currently registered clinical trials was performed on registries, including the Chinese (chictr.org.cn) and US (clinicaltrials.gov) databases to identify relevant studies up to March, 7th 2020. The search was conducted using the search terms “2019-nCoV”, “COVID-19”, “SARS-CoV-2”, “Hcov-19”, “new coronavirus”, “novel coronavirus”. We included interventional clinical trials focusing on patients with COVID-19 and assessing antiviral drugs or agents.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.18.20038190v1
19浏览量
原文链接
相关报告

  • 《MedRixv，3月3日，Systematic Review of the Registered Clinical Trials of Coronavirus Diseases 2019 (COVID-19)》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-04
    • Systematic Review of the Registered Clinical Trials of Coronavirus Diseases 2019 (COVID-19) Rui-fang Zhu, Ru-lu Gao, Sue-Ho Robert, Jin-ping Gao, Shi-gui Yang, Changtai Zhu doi: https://doi.org/10.1101/2020.03.01.20029611 Abstract Background: Since the outbreak of coronavirus diseases 2019 (COVID-19), many researchers in China have immediately carried out clinical research scheme of the COVID-19. But, there is still a lack of systematic review of registered clinical trials. Therefore, we made the first systematic review of the clinical trials of COVID-19 in order to provide evidence for the control of the COVID-19. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    15浏览量
    原文链接

  • 《MedRxiv，3月8日，Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-09
    • Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review Ruijin Qiu, Xuxu Wei, Mengzhu Zhao, Changming Zhong, Chen Zhao, Jiayuan Hu, Min Li, Ya Huang, Songjie Han, Tianmai He, Jing Chen, Hongcai Shang doi: https://doi.org/10.1101/2020.03.04.20031401 Abstract Objectives: To examine heterogeneity of outcomes in protocols of clinical trials of Coronavirus Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core outcome set (COS) in this field. Design: This study is a review. Data sources: Databases of ICMJE-accepted clinical trial registry platform were searched on February 14, 2020. Eligibility Criteria: Randomized controlled trials (RCTs) and non-RCTs of COVID-19 were considered.Conditions of patients include common type, severe type or critical type. Interventions include traditional Chinese medicine (TCM) and Western medicine. We excluded trials that for discharged patients, psychological intervention and complications of COVID-19. Data extraction and synthesis: The general information and outcomes, outcome measurement instruments and measurement times were extracted. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    104浏览量
    原文链接